Duchenne News

June 20, 2024
Breaking news: US FDA has expanded approval of Sarepta Therapeutics’ gene therapy, Elevidys to Duchenne muscular dystrophy patients ages 4 and above. Elevidys has received traditional FDA approval for ambulatory...
June 4, 2024
Patients treated with CAP-1002 continue to show positive benefits after 3 years of treatment in both the PUL 2.0 and LVEF measures when compared to an external comparator dataset of...
May 20, 2024
On May 20, 2024, PTC Therapeutics announced that the European Commission (EC) has decided not to adopt the CHMP’s negative opinion of January 24, 2024 on the annual renewal of...
May 20, 2024
On Monday, May 20, Dyne Therapeutics announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its ongoing Phase...
May 10, 2024
REGENXBIO shares financial results for the first quarter ending March 31, 2024.
May 7, 2024
Tuesday, May 7, 2024 – We at Jett Foundation are deeply saddened to learn about the devastating loss of a child participating in Pfizer’s Phase 2 DAYLIGHT clinical trial for...
May 3, 2024
Pfizer shares that FDA has granted RMAT designation for gene therapy in development for Duchenne.
April 26, 2024
Capricor Therapeutics announces update on next steps for the Biologics License Application submission with its lead asset CAP-1002 in treating Duchenne muscular dystrophy.
April 23, 2024
BioMarin shares updates on their Clinical Trial Programs.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open